Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 2:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 9,942 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infectious Clear all

Conditions: Complicated Urinary Tract Infection Including Acute Pyelonephritis
Interventions: Combination of Imipenem/Cilastatin and XNW4107, Meropenem; Drug
Lead sponsor: Evopoint Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Infection, E Coli Infections, Klebsiella Infections, Proteus Infections
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Candida, Candidiasis
Interventions: Anidulafungin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cesarean Section Complications, Cesarean Section; Infection
Interventions: Irrisept, Normal Saline; Device · Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: COVID-19, Undefined
Interventions: AT-100; Biological
Lead sponsor: Airway Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Clostridium Difficile Infection (CDI)
Interventions: Fidaxomicin, Vancomycin; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Ypsilanti, Michigan

Conditions: HIV Infections
Interventions: Raltegravir; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: HIV/AIDS
Interventions: Enhanced PrEP Adherence, Standard PrEP Adherence; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 204 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: New York, New York

Conditions: HIV Seropositivity
Interventions: Computer-based simulation training for providers, Best Practice Alert, HIV Risk Assessment, PrEP Informational Video; Behavioral
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 1,380 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: HIV Infections
Interventions: Interferon alfa-2a, Zidovudine, Zalcitabine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 4
States / cities: Birmingham, Alabama • La Jolla, California • San Diego, California + 1 more

Conditions: COVID, COVID19, SARS-CoV 2, Dyspnea
Interventions: Data Collection; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 11,973 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Impaired Cognition, HIV Infection
Interventions: MBSR; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 55 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: SARS-CoV-2 Infection, COVID-19, Coronavirus Infection, SARS (Severe Acute Respiratory Syndrome)
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 10 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HIV Infections
Interventions: Zidovudine, Aldesleukin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 1
States / cities: Stanford, California

Conditions: Appendicitis (Diagnosis)
Interventions: Cefoxitin; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Acute HIV Infection
Interventions: Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Chlamydia Trachomatis, Gonorrhea
Interventions: home testing kit; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 15 Years to 29 Years · Female only
Enrollment: 403 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Common Wart
Interventions: A-101 Topical Solution, A-101 Vehicle Solution; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 8 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 17
States / cities: Scottsdale, Arizona • Rogers, Arkansas • San Diego, California + 13 more

Conditions: Hepatitis B, Chronic
Interventions: Entecavir, Entecavir + Tenofovir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 16 Years and older
Enrollment: 669 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 16
States / cities: Los Angeles, California • San Diego, California • San Jose, California + 10 more

Conditions: HIV I Infection
Interventions: VIR-1111, Placebo; Biological · Drug
Lead sponsor: Vir Biotechnology, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Miami, Florida • Seattle, Washington • Madison, Wisconsin

Conditions: HPV Infection, HPV Vaccine
Interventions: HPV vaccine; Biological
Lead sponsor: University of Washington; Other
Eligibility: 27 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Human Papillomavirus (HPV) Infection
Interventions: Endometrics Menstrual Blood Collection Kit; Device
Lead sponsor: Samantha Batman; Other
Eligibility: 21 Years to 49 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Covid19
Interventions: GSE and Xylitol, Control Placebo; Other · Drug
Lead sponsor: Larkin Community Hospital; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Miami, Florida

Conditions: HPV Infection
Interventions: pBI-11 (3 doses), pBI-11 (1 dose), Placebo (2 doses); Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Birmingham, Alabama • Baltimore, Maryland

Search by objective public record fields.

Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)

Community - Associated Extended-spectrum Beta-lactamases (ESBL)

Anidulafungin Versus Fluconazole in the Treatment of Candidemia

Wound Irrigation With Saline Versus Hypodilute-chlorhexidine After Cesarean Section (WISHES Study)

A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia

A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections

RAL-eve Study: Raltegravir Substitution Study

PrEPared and Strong: Clinic-Based PrEP for Black MSM

A Multilevel, Multiphase Optimization Strategy for PrEP (MOST:PrEP)

A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3

International SARS-CoV-2 (COVID-19) Infection Observational Study

Mindfulness Based Stress Reduction for Older Adults With HIV Associated Neurocognitive Disorders

Index Individuals in SARS-CoV-2 Prevention Research Studies (COVID-19 Index Individuals Companion Study)

Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients With Persistent Generalized Lymphadenopathy

Precision Antibiotic Dosing for Appendectomy

Empiric Treatment for Acute HIV in the ED

Home Screening for Chlamydia Surveillance

A Phase2 of A-101 Topical Solution in Subjects With Common Warts

Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B

VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers

Intradermal, Fractional Dose of HPV Vaccines:

HPV Detection Using Self-Collected Menstrual Blood

Impact of GSE and Xylitol (Xlear) on COVID-19 Symptoms and Time to PCR Negativisation in COVID-19 Patients

Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+